UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Granulomatous Mastitis: A Therapeutic and Diagnostic Challenge

Breast care (Basel, Switzerland), 2018-12, Vol.13 (6), p.413-418

2018

Link zum Volltext

Verfügbarkeit prüfen

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

The lancet oncology, 2022-05, Vol.23 (5), p.625-635

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

International journal of cancer, 2020-01, Vol.146 (1), p.262-271

2020

Link zum Volltext

Verfügbarkeit prüfen

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.503-503

2021

Link zum Volltext

Verfügbarkeit prüfen

BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial

International journal of cancer, 2016-08, Vol.139 (4), p.882-889

2016

Link zum Volltext

Verfügbarkeit prüfen

Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet

Breast care (Basel, Switzerland), 2021-10, Vol.16 (5), p.475-483

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT3-2-03: Prospective observational study of clinical outcomes for the NanoString® technologies Prosigna™ test by the West German Study Group

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT3-2-03-OT3-2-03

2015

Link zum Volltext

Verfügbarkeit prüfen

Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid‐papillary carcinoma

The journal of pathology. Clinical research, 2017-07, Vol.3 (3), p.191-202

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial

Breast cancer research and treatment, 2015-04, Vol.150 (2), p.279-288

2015

Link zum Volltext

Verfügbarkeit prüfen

BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.11018-11018

2014

Link zum Volltext

Verfügbarkeit prüfen

Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.535-535

2015

Link zum Volltext

Verfügbarkeit prüfen

The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1092-1092

2013

Link zum Volltext

Verfügbarkeit prüfen

Herausforderungen für ein Next Generation Biobanking – Kryokonservierung für die Weiterentwicklung der personalisierten Medizin

Immunoassays, 2023, p.617-636

2023

Link zum Volltext

Verfügbarkeit prüfen

Einführung in Immunoassays

Immunoassays, 2023, p.1-20

2023

Link zum Volltext

Verfügbarkeit prüfen

Auer rods in mature granulocytes in peripheral blood

International journal of hematology, 2024-02, Vol.119 (2), p.105-106

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(19)
Buchkapitel
(2)

Sprache

Englisch
(19)
Deutsch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Granulomatous Mastitis: A Therapeutic and Diagnostic Challenge

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial

Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results

BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial

Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet

Abstract OT3-2-03: Prospective observational study of clinical outcomes for the NanoString® technologies Prosigna™ test by the West German Study Group

Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial

Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid‐papillary carcinoma

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial

BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial

Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition

The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial

Herausforderungen für ein Next Generation Biobanking – Kryokonservierung für die Weiterentwicklung der personalisierten Medizin

Einführung in Immunoassays

Auer rods in mature granulocytes in peripheral blood

Suchergebnisse filtern